RxDoctor Payments Data

Heather Yannuzzi

Primary Care · Wyomissing, PANPI 1619410016

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,508 of the $2,916 with a category attached, or 86.0%. 12 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 27.8% of the total. Reporting peaked in 2024 at $1,091 and has fallen 74.2% since, to $282 in 2025. Among primary care clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,916in general payments, 2019–2025

Across 146 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$812
  • Johnson & Johnson$667
  • ANI Pharmaceuticals, Inc.$429
  • AbbVie$247
  • Lilly USA, LLC$198
  • Amgen$189
  • plus $373 from 6 others

What the payments were for

  • Food & beverage$2,50886%
  • Education$40814%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,916 in reported general payments places this provider in the 90th percentile of 300 primary care providers in Pennsylvania.

See all primary care providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$304,223
Medicare patients
402
Services billed
20,965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab53$377,221
Enbrel SureclickEtanercept23$168,757
Orencia ClickjectAbatacept15$97,235
Humira(Cf)Adalimumab13$87,484
KevzaraSarilumab17$72,408
Hydroxychloroquine Sulfate246$11,080
MethotrexateMethotrexate Sodium323$6,762
Prednisone316$2,041
Sulfasalazine DrSulfasalazine63$1,913
Duloxetine Hcl33$1,848
Celecoxib33$1,246
Tramadol Hcl119$1,246
Gabapentin90$1,090
Leflunomide24$986
Alendronate Sodium70$857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf)$247$87,48413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 300 primary care providers in Pennsylvania.

Other primary care in Wyomissing

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →